Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monovalent Cations
100%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
100%
Omicron BA.1
100%
Titer
40%
ID50
40%
Immunogenicity
20%
Protein-based
20%
Systemic Side Effects
20%
Randomized Clinical Trial
20%
Vaccine Protection
20%
Neutralizing Antibodies
20%
COVID-19
20%
Non-associated
20%
Adverse Events
20%
Confidence Interval
20%
Serious Adverse Events
20%
Monovalent Vaccine
20%
Neutralizing Titer
20%
Bivalent Vaccine
20%
Vaccine Target
20%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
20%
D614G
20%
Spike Antigen
20%
Omicron Sub-lineages
20%
Pseudovirus Neutralization
20%
Omicron BA.4
20%
Ancestral Strain
20%
Adverse Events of Special Interest
20%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Omicron Coronavirus Variant
100%
Titer
42%
Neutralization
42%
Wild Type
28%
ID50
28%
Antibody Response
14%
Immunogenicity
14%
Neutralizing Antibody
14%
Dilution
14%
Spike
14%
Arm
14%
Infection
14%
Biochemistry, Genetics and Molecular Biology
SARS Coronavirus
100%
Omicron
100%
Titer
42%
Wild Type
28%
ID50
28%
Immunogenicity
14%
Randomized Clinical Trial
14%
Spike
14%
Dilution
14%
Neutralizing Antibody
14%
Antibody Response
14%
Messenger RNA
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
SARS Coronavirus
100%
Infection
25%
Immunogenicity
25%
Randomized Clinical Trial
25%
Neutralizing Antibody
25%
Messenger RNA
25%